Aquatic Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Aquatic Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$548K	Buy	+28,134	New	+$510K	0.02%	764
2025 Q4	–	Sell	-7,890	Closed	-$56.6K	–	1623
2025 Q3	$56.6K	Sell	7,890 -9,436	-54%	-$492K	﹤0.01%	1270
2025 Q2	$818K	Buy	17,326 +17,244	+21,029%	+$702K	0.02%	702
2025 Q1	$3.2K	Buy	+82	New	+$3.53K	﹤0.01%	1202

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aquatic Capital Management's MLTX Position: Q2 2026 in Review

Aquatic Capital Management opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 28,134 shares worth $548K. The stake represents 0.02% of the portfolio and ranks #764 among its holdings. This is a return to the name: Aquatic Capital Management previously reported a position in MLTX as recently as Q3 2025.

Aquatic Capital Management first reported a position in MLTX in Q1 2025 and has held it in 4 quarters since. The position peaked at $818K in Q2 2025. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Aquatic Capital Management held 28,134 shares of MoonLake Immunotherapeutics worth $548K as of Q2 2026.
MoonLake Immunotherapeutics was a new Aquatic Capital Management position in Q2 2026.
MoonLake Immunotherapeutics made up 0.02% of Aquatic Capital Management's portfolio in Q2 2026, its #764 holding.
Aquatic Capital Management first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 4 quarters since.
Aquatic Capital Management's MoonLake Immunotherapeutics position peaked at $818K in Q2 2025.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.